A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

They evaluated pembrolizumab in patients with resectable stage II-IV (M0) cSCC. Patients received 200 mg pembrolizumab every 3 weeks for 4 cycles, followed by 18F-labeled fluorodeoxyglucose-positron ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

“I didn’t have any of the typical symptoms like blood in my poo, so the diagnosis came as a massive shock,” said Zara. Zara ...

A global study reveals that cutting-edge cancer immunotherapies, while lifesaving, carry a hidden risk: they may trigger ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. CG Oncology, Inc. stands sixth on our list. CG Oncology, Inc ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Exelixis' revenue growth through cabozantinib, mixed trial updates on zanzalintinib, and potential market shifts following ...